MEMBERS Trust Co lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,121 shares of the company’s stock after purchasing an additional 698 shares during the quarter. Johnson & Johnson accounts for approximately 0.1% of MEMBERS Trust Co’s portfolio, making the stock its 26th largest position. MEMBERS Trust Co’s holdings in Johnson & Johnson were worth $1,656,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Newfound Research LLC purchased a new stake in Johnson & Johnson in the third quarter worth approximately $28,000. Islay Capital Management LLC purchased a new stake in Johnson & Johnson in the second quarter worth approximately $42,000. FAI Wealth Management boosted its stake in Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC boosted its stake in Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares in the last quarter. Finally, HWG Holdings LP purchased a new stake in Johnson & Johnson in the second quarter worth approximately $49,000. 67.44% of the stock is owned by institutional investors.
Shares of Johnson & Johnson stock opened at $146.36 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The company has a market cap of $385.30 billion, a PE ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. The business has a 50 day moving average of $145.51 and a 200 day moving average of $146.57. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
Several analysts have issued reports on the company. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald boosted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Credit Suisse Group boosted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $164.93.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: What is a recession?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.